Antibiotic Resistance

Drug-resistant strains of bacteria are prevalent in both hospital and community settings; they cause billions of dollars in avoidable health costs and cause unnecessary disability and death. If left unaddressed, antibiotic resistance could recreate a world in which invasive surgeries are impossible and people routinely die from simple bacterial infections.
 
CDDEP views antibiotic effectiveness as a shared resource: using an antibiotic now increases the opportunity for bacteria to develop resistance and thus reduces our ability to use that antibiotic in the future. Addressing antibiotic resistance is difficult because patients, physicians, hospitals, pharmaceutical companies, and agricultural users have insufficient incentives to act in ways that would conserve antibiotic effectiveness.
 
These challenges suggest the simultaneous deployment of multiple strategies: vaccination to prevent illness and reduce demand for antibiotics, aggressive hospital infection control, judicious prescribing and cycling of antibiotics, treatment with narrow-spectrum antibiotics, development of new antibiotics, and a coordinated federal policy that stewards this resource. 
 
CDDEP’s Extending the Cure report has informed legislative efforts in the United States to improve infection control in hospitals and manage antibiotic effectiveness as a shared societal resource. A policy that recognizes how incentives shape the behavior of all players will likely be more effective than regulation or information alone. 
 
CDDEP’s Global Antibiotic Resistance Partnership is developing actionable policy proposals for India, Kenya, South Africa, and Vietnam. Researchers are identifying weaknesses in how antibiotics are developed and regulated and how antibiotic use and resistance are tracked. The expertise developed in these five countries will be the core of a wider partnership that helps policymakers in other low- and middle-income countries control antibiotic resistance as part of a worldwide effort.
 

Events

Tuesday, September 20, 2016 - 04:00 to 06:30
Tuesday, April 5, 2016 - 15:00 to 16:00
Lipsett Amphitheatre, NIH
Lipsett Amphitheater (inside Building 10/ Clinical Center on the NIH campus), Bethesda, Md.
Tuesday, March 29, 2016 - 14:45
Great Hall, Hubert H. Humphrey Building
200 Independence Ave., SW, Washington, DC 20201
Sunday, November 2, 2014 - 08:00
NCPA Mumbai
NCPA Marg, Nariman Point, Mumbai, MH 400021, India

Tools

This map shows the countries that have reported plasmid-mediated colistin resistance conferred by mcr-1. 
Presentation from CDDEP Associate Director Hellen Gelband and CDDEP Research Associate Molly Miller-Petrie, given at the GARP-Bangladesh and GARP-Pakistan Inaugural Meeting, July 14-15, 2016, in Kathmandu, Nepal.